Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib vs Doxorubicin in Advanced Endometrial Carcinoma
NCT03005015Phase 2Withdrawn
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jan 2017
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib in endometrial carcinoma, sponsored by European Organisation for Research and Treatment of Cancer. Planned start Jan 2017; status: withdrawn.
02
Drugs
lenvatinib
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT03005015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03005015.